Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access to Exjade (deferasirox) for transfusion-related iron overload in congenital red blood cell disorders
2005-001290-10Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in hemochromatosis (HH) and Congenital red blood cell disorder, sponsored by Novartis. Primary endpoint: Safety. Started Oct 2005; status: completed.
02
Drugs
deferasirox
03
Conditions
hemochromatosis (HH)Congenital red blood cell disorder
Beyond the preview
Go deeper on 2005-001290-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001290-10.